IV gentamicin shows promise for genetic blistering skin disorder
Systemic readthrough therapy promotes wound closure in paediatric patients with junctional epidermolysis bullosa, US clinicians say
A single course of IV gentamicin may be a safe and readily available systemic therapy for patients with junctional epidermolysis bullosa, according to results from a small pilot trial.
While the long-term safety and efficacy remains unknown, US researchers say their findings provide a glimmer of hope for those born with the incurable blistering skin disorder.